Bacteriology and Infectious Diseases

Biography

Dr. Ananda M. Chakrabarty serves as Senior Science Advisor of Amrita Therapeutics Limited. Dr. Chakrabarty is a Amrita’s Senior Science Mentor and Global Domain Expert relating to how bacterial proteins effectively combat cancers, parasites, and viruses in the human body. Dr. Chakrabarty serves as a Distinguished University Professor of Microbiology and Immunology at the University of Illinois College of Medicine, and advises senior officials in the U.S. and abroad on policies relating to biotechnology and related technology transfer. He is a Consultant to the United Nations. In 1980, Dr. Chakrabarty’s genetically modified Pseudomonas bacteria became the first genetically-engineered organism to gain a patent, as a result of the Supreme Court decision in Diamond vs. Chakrabarty. Dr. Chakrabarty undertook pioneering biotechnology research into the therapeutic potential for protein products of bacteria, both at the University of Illinois at Chicago (UIC) and on behalf of CDG Therapeutics, a U.S. biotechnology start-up company engaged in clinical cancer research. Dr. Chakrabarty has led path-breaking research into the therapeutic qualities of protein products of bacteria. His work includes recent studies with water-soluble products of pathogenic bacteria demonstrating significant promise for cancer therapies, effective against HIV/AIDS, malaria and perhaps even tuberculosis. Dr. Chakrabarty was a part of the Advisory Committee that resulted in creation of the International Center for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy and rejoined the ICGEB Advisory Board. Dr. Chakrabarty has numerous publications and has received many notable awards for his contributions to biotechnology, including Padma Shri in 2007, one of the Indian Government’s highest civilian honors.

Research Interest

Cell Biology, Microbiology, Pseudomonas aeruginosa, Cancer Cells, Biotechnology, Oncology, Cancer Biology, Cancer Therapy, Pseudomonas, Malaria, Cystic Fibrosis, Genetic Engineering, Infectious Diseases, Cancer Chemotherapy, Mutation